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Background: The impact of both cancer and its treatment on bone is an essential component of
oncological practice. Bone oncology not only affects patients with both early stage and metastatic
disease but also covers the entire spectrum of tumour types. We therefore decided to review and
summarise bone oncology-related trials that are currently being conducted in Canada.
Method: We assessed ongoing and recently completed trials in Canada. We used available North
American and Canadian cancer trial websites and also contacted known investigators in this ﬁeld for
their input.
Results: Twenty seven clinical trials were identiﬁed. Seven pertained to local treatment of bone metastasis
from any solid tumour type. Seven were systemic treatment trials, ﬁve focused on bone biology and
predictive factors, three evaluated safety of bone-targeted agents, three were adjuvant trials and two trials
investigated impact of cancer therapy on bone health. The majority of trials were related to systemic
treatment and bone biology in breast cancer. Most were small, single centre, grant-funded studies. Not
surprisingly the larger safety and adjuvant studies were pharmaceutical company driven.
Discussion: Despite the widespread interest in bone-targeted therapies our survey would suggest that most
studies are single centre and breast cancer focused. If major advances in bone oncology are to be made then
collaborative strategies are needed to not only increase current sample sizes but to also expand these
studies into non-breast cancer populations.
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bone oncology is an increasingly important area of cancer
therapeutics. It covers a number of areas including; the effects of
normal aging on bone, the treatment and prevention of cancer
therapy-induced bone loss and strategies for prevention of bone
metastases and reducing skeletal related events in those with
metastatic disease. Historically the greatest emphasis has been on
bone metastasis management, as skeletal metastases are common
and a signiﬁcant cause of patient morbidity. Although any
malignancy may ultimately metastasize to bone, it is most
prevalent in advanced breast (70–80%), prostate (70–80%), thyr-
oid (60%) and lung cancers (10–50%) [1]. Given that breast and
prostate cancers are the most common cancers to afﬂict women
and men respectively, it is not surprising that most research has
focused on these sites. More recently there has been increased
interest in the effects of cancer therapy-induced bone loss due to
chemotherapy (directly and through induction of premature. This is an open access article un
, The Ottawa Hospital Cancer
3 737 7700x70170;
s).ovarian failure) and anti-estrogen/androgen therapies. Again, this
is particularly pertinent in breast and prostate cancers. In addi-
tion, large adjuvant therapy trials with bisphosphonates and
denosumab are also being evaluated in patients with breast and
prostate cancers [2,3,4,5].
Research into bone health has to reﬂect the multi-modality,
multi-disciplinary and broad interests of those involved. These
can include such diverse groups as; medical oncologists, radiation
oncologists, surgical oncologists, palliative care specialists, endo-
crinologists, nursing, orthopaedics, basic scientists, imaging and
primary care providers, to name but a few. It is therefore essential
that a portfolio of trials exists to reﬂect this. We also require a
means of educating, identifying, and linking all those interested in
bone oncology to help initiate and sustain relevant collaborations.
The purpose of this paper is to brieﬂy review and summarise bone
oncology-related trials that are currently being conducted in
Canada to facilitate this process.2. Methods
We reviewed http://www.canadiancancertrials.ca/ and http://
www.ontario.canadiancancertrials.ca/ in order to identify ongoingder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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metastasis, bone treatment, cancer therapy induced bone loss and
bisphosphonates for searching. We also used http://clinicaltrials.
gov/ to identify Canadian participation in international studies.
We also contacted colleagues in cancer centres across Canada for
additional information about local studies at their own centres.3. Results
Due to the diversity of effects of cancer and its treatment on
bone health our search identiﬁed a number of bone oncology
research themes including; local palliative therapy for sympto-
matic metastases, systemic treatment of bone metastases, the
safety of systemic treatment, adjuvant therapy trials with bone-
targeted agents and studies investigating cancer therapy induced
bone loss. There were also a number of biomarker studies
evaluating the utility of predictive factors for skeletal related
events or designed to increase our understanding about funda-
mental bone biology. A number of Canadian groups perform basic
and translational bone research. We will discuss each theme
in turn.3.1. Local therapy studies
A diverse range of local therapy trials are being performed
(Table 1). These reﬂect the palliative effects of radiotherapy,
focused ultrasound, or surgery on symptomatic bone metastases.
These studies involved patients with a range of primary cancers.
Six of the seven currently running trials of local therapy for bone
metastases were multi-centre. Four of them were intergroup
initiated, one was sponsored by industry, and one was academic
grant-funded.Table 1
Local therapy trials for patients with bone metastases.
Study title Primary end-point
A Phase III international randomized trial
of single versus multiple fractions for
re-irradiation of painful bone metastases [6]
Compare pain relief in patients
single-fraction versus multiple-
irradiation of painful bone met
after treatment.
A phase III study of the effect of re-irradiation
for bone pain on urinary markers of
osteoclast activity [7]
To correlate the response of re-
change of urinary markers of o
Dexamethasone versus placebo in the
prophylaxis of radiation-induced pain ﬂare
following palliative radiation therapy for
bone metastases [8]
Reduction in incidence of radia
pain ﬂare after single 8 Gy frac
time of radiotherapy treatment
the completion of treatment
A prospective cohort study of the role of
surgery and/or radiation therapy for bone
metastases of the femur at high risk of
pathological fracture (observational) [9]
To describe the ambulatory sta
by intervention (surgery7radi
radiotherapy alone group)
Surgical versus non-operative treatment of
metastatic epidural spinal cord
compression. quality of life and cost-
effectiveness outcomes (observational) [10]
Change in spine-associated pai
neurological outcomes
A pivotal study to evaluate the effectiveness
and safety of ExAblate (magnetic resonance-
guided focused ultrasound surgery)
treatment of metastatic and multiple
myeloma bone tumors for the palliation of
pain in patients who are not candidates for
radiation therapy, phase III [11]
Improvement in pain scores
Phase II/III study of image-guided
radiosurgery/SBRT for localized spine
metastasis [12]
Efﬁcacy and safety of radiosurg3.2. Systemic treatment trials for patients with bone metastases
Bisphosphonates and RANKL inhibitors have been shown to be
effective in reducing the frequency and increasing time to onset of
skeletal related events in patients with bone metastases. How-
ever, there are many unresolved questions around their use,
including questions regarding; duration of use, optimal interval
between treatments, choice of agent, as well as strategies to
reduce side effects of therapy. Although current treatment
recommendations are the same for all patients with metastatic
bone disease (usually 3 to 4 weekly systemic therapy), patients
with low risk of skeletal-related events probably need less
aggressive dosing regimens, while patients at the highest risk of
skeletal complications need more effective treatment.
Several ongoing trials are trying to optimise the management
of patients with bone metastases using bone turnover markers as
surrogates of skeletal related event risk (Table 2). These studies
can be broadly split into those assessing the magnitude and/or
duration of biomarker suppression [13–16], reduced bisphospho-
nate use [17], and those evaluating optimal care of patients with
high risk disease [18]. Almost all these trials are in breast cancer
patients. In prostate cancer there was one large randomized Phase
III study evaluating the efﬁcacy of early versus standard zole-
dronic acid in prevention of SREs in patients with prostate cancer
metastatic to bone on androgen-deprivation treatment [19].
Unlike the local therapy trials described above most of the
systemic therapy studies were small, single centre, investigator-
initiated, and funded either by peer-reviewed grants or internal
funding. One study was multinational, and sponsored by NCI and
CALGB [19]. Another multi-centre study was initiated and spon-
sored by the Ontario Clinical Oncology Group with pharmaceu-
tical funding [16]. Understandably systemic therapy safety
(Table 3), adjuvant trials (Table 4) tended to be multinational
and pharmaceutical company funded. Two Canadian prospective
studies investigating cancer treatment induced bone loss in prostateNumber of
centres
Number of
patients
Cancer
type
undergoing
fraction re-
astases 2 months
Multi-centre 850 Any
irradiation to the
steoclast activity
Multi-centre 130 Any
tion-induced
tion from the
to 10 days after
Multi-centre 300 Any
tus at 3 months
otherapy, and
2 Ontario centres 180 Any
n intensity and Multi-centre 432 Any
Multi-centre 148 Any
ery Multi-centre 280 Any
Table 2
Systemic therapy trials for patients with metastatic bone disease.
Study Title Study arm Primary end-point Number
of centres
Number of
patients
Cancer
type
A randomized pilot study comparing
the efﬁcacy of 4-weekly versus
12-weekly intravenous
bisphosphonate therapy in women
with low risk bone metastases from
breast cancer using bone resorption
markers [13]
Randomised comparison
of 4 weekly versus 12-
weekly pamidronate
To demonstrate that the
administration of pamidronate once
every 12 weeks is equivalent to 3–4
weekly administration
1 37 Breast
Suppression of bone turnover
following treatment with zoledronic
acid in patients with metastatic
breast cancer: duration of effect [14]
Single arm, single
infusion of zoledronic
acid
To estimate the proportion of
patients with suppression of bone
turnover at 12 weeks after
administration of a single dose of
zoledronic acid
1 35 Breast
Duration of suppression of bone
turnover following treatment with
zoledronic acid in men with
metastatic castration resistant
prostate cancer [15]
Single infusion of
zoledronic acid
Duration of suppression of bone
turnover in prostate cancer patients
with bone metastases following a
single infusion of Zoledronic Acid
and its effect on quality of life.
2 50 Prostate
A phase ii, multi-centre, randomized,
double-blind trial to evaluate the
therapeutic beneﬁt of Fulvestrant in
combination with ZACTIMA or
Fulvestrant Plus Placebo in
postmenopausal women with bone
only or bone predominant, hormone
receptor positive metastatic breast
cancer [16]
FulvestrantþZactima
versus
FulvestrantþPlacebo
Signiﬁcant change in NTx level
deﬁned as aZ30% reduction in
urinary NTx level from baseline
Multi-
centre
126 Breast
A multicentre study assessing 12-
weekly intravenous bisphosphonate
therapy in women with low risk
bone metastases from breast cancer
using bone resorption markers [17]
Single arm, 12-weekly
pamidronate
To demonstrate that in women with
biochemical evidence of lower risk
bone metastases following at least
three months of regular 3–4 weekly
pamidronate, the administration of
pamidronate once every 12 weeks
is sufﬁcient to maintain this
biochemical stability for one year
1 68 Breast
A randomized, double-blind, placebo
controlled, Phase III trial evaluating
the palliative beneﬁt of either
continuing pamidronate or switching
to second-line zoledronic acid in
breast cancer patients with high risk
bone metastases [18]
4 weekly pamidronate
versus zoledronic acid
To compare the proportion of high-
risk metastatic breast cancer
patients with bone metastases that
will achieve a decrease in sCTX in
the zoledronic and pamidronate
treatment arms.
1 84 Breast
A randomized, double-blind, placebo-
controlled phase iii study of early
versus standard zoledronic acid to
prevent skeletal related events in
men with prostate cancer metastatic
to bone [19]
4 weekly zoledronic acid
versus placebo
Time to 1st SRE Multi-
centre
680 Prostate
Table 3
Trials assessing safety of systemic therapies.
Study title Primary end-point Number of
centres
Number of
patients
Cancer type
An Open-label, multi-centre, phase
2 study of denosumab in subjects with
giant cell tumour of bone [20]
Safety proﬁle of denosumab characterized
in terms of the type, frequency, and
severity of adverse events and laboratory
abnormalities
Multi-centre 375 Giant cell tumour
of bone
A double-blind, placebo-controlled
study to evaluate new or worsening
lens opaciﬁcations in subjects with
non-metastatic prostate cancer
receiving denosumab for bone
loss due to androgen-deprivation
therapy [21]
Subject incidence of cataract event
development or progression on
denosumab by month 12 exceeding a
predeﬁned level at any of 3 key lens
locations using LOCS III score
Multi-centre 760 Prostate non-
metastatic
Feasibility and dose discovery analysis
of zoledronic acid with concurrent
chemotherapy in the treatment of
newly diagnosed metastatic
osteosarcoma [22]
Safety, dose-limiting toxicity and
maximum tolerated dose of zoledronic
acid
Multi-centre 30 Osteosarcoma
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Table 5
Studies related to cancer therapy induced bone loss.
Study title Primary endpoint Current status Number of
centres
Numbers of
patients
Cancer
type
A randomized, single-blind, placebo-controlled, multicentre study to
evaluate the effect of risedronate and placebo on bone mineral
density in men undergoing androgen deprivation therapy with
leuprolide acetate [25]
Bone mineral density
of the lumbar spine
after 12 months
Completed- results
awaiting
Multicenter 160 Prostate
A prospective study to evaluate the incidence of skeletal related
events in prostate cancer patients undergoing Androgen
Deprivation Therapy (ADT) [26] prospective observational
Bone mineral density
of the lumbar spine
Ongoing but not
recruiting patients
Multicenter 300 Prostate
Table 6
Studies evaluating bone biology and biomarkers of skeletal risk.
Project title Primary end-point Number of
centres
Number of
patients
Cancer
type
Prospective identiﬁcation of risk factors for skeletal related
events in breast cancer patients receiving bisphosphonates
for bone metastases [27]
Identiﬁcation of risk factors for SREs in breast cancer patients 1 60 Breast
Histomorphometric and microarhitectural analyses using the
2 mm bone marrow trephine in metastatic breast cancer
(MBC) patients on long term bisphosphonate therapy—a
feasibility study [28]
Feasibility of bone biopsy using 2 mm needle to look at the way
bisphosphonates change the structure of the bone after extended
use
3 30 Breast
Bone repository feasibility study in breast, prostate and lung
patients [29]
To evaluate if 2 mm needle bone biopsy can provide enough
tissue to make all
1 30 Breast,
prostate,
lung
Breast cancer to bone (B2B) metastases research program: a
multidisciplinary approach to the investigation of bone
metastases from breast cancer [30]
4 Subgroups: identiﬁcation of predictor factors for bone
metastases in patients with early stage breast cancer
1 600 Breast
A Phase 2 trial exploring the clinical and correlative effects of
combining doxycycline with bone-targeted therapy in
patients with metastatic breast cancer [31]
To assess the palliative beneﬁt (reﬂected through changes in
validated pain scores and the bone resorption marker serum
C-telopeptide) of adding doxycycline to standard bone-targeted
therapy in women with breast cancer and bone metastases
1 37 Breast
Table 4
Adjuvant bone-targeted therapy trials.
Study title Primary
end-point
Current
status
Number of centres Number of
patients
Cancer
type
A randomized, double-blind, placebo-controlled, multi-
centre phase 3 study of denosumab as adjuvant treatment
for women with early-stage breast cancer at high risk of
recurrence (D-CARE) [23]
DFS Recruiting Multi-centre 4500 Breast
Randomized phase iii trial of bisphosphonates as adjuvant
therapy for primary breast cancer [24]
DFS, OS Closed for
accrual
Multi-centre 5400 Breast
A clinical trial comparing adjuvant clodronate therapy
versus placebo in early-stage breast cancer patients
receiving systemic chemotherapy and/or hormonal
therapy or no therapy [4]
DFS Closed to
accrual
Multi-centre 3323 Breast
DFS¼Disease free survival, OS¼Overall survival.
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tical companies (Table 5).3.3. Studies of bone biology and predictive markers
A number of investigations are ongoing to evaluate funda-
mental biology in bone and also prospectively identify useful
biomarkers of bone metastasis aggression and behaviour, or
prediction of future bone metastasis risk (Table 6). Again these
studies tended to be focused on breast cancer patients. Prospec-
tively collected specimens from three studies [13,17,18] have
been used to identify risk factors for skeletal related events in
breast cancer patients receiving bisphosphonates and also risk for
developing bone metastases in the ﬁrst place.Given the paucity of in vivo information about the effects of
bone targeted agents on human tissue two studies are of
particular interest. In one study [27], patients with bone
metastases from breast cancer are being prospectively evaluated
to determine whether standard or novel assessment of bone
density, bone quality, and/or markers of bone breakdown are
useful in stratifying the skeletal related event risk of individual
patients. In another study [28] evaluating long term bispho-
sphonate therapy on bone homeostasis, quality, quantity, and
bone architecture is being explored. Patients with metastatic
breast cancer on long term bisphosphonate are undergoing
histomorphometric and micro-architectural analyses of 2 mm
bone marrow trephine biopsies to assess bone quality, as well
as standard DEXA assessments of bone quantity. Another bone
biopsy study will evaluate whether trephine needle bone biopsy
I. Kuchuk et al. / Journal of Bone Oncology 1 (2012) 95–100 99can provide enough tissue for banking in patients with lung,
prostate and breast cancers [29].
The, ‘‘Breast cancer to bone (B2B)’’ metastases research pro-
gram is a large multidisciplinary population study funded by the
Alberta Cancer Foundation. This project collects clinical, patholo-
gical and biochemical data for the investigation of predictive
factors for bone metastases in patients with early stage breast
cancer. Patients are followed prospectively from the time of
diagnosis of breast cancer until they develop bone metastases.
This study has recently been expanded to collect tissue and data
from patients with a range of malignancies [30].
Preclinical studies showed that doxycyclin enhance an anti-
tumour activity of bone targeted agents on bone metastases
models. A phase II study exploring clinical efﬁcacy of combination
bone targeted agents with doxycyclin is open to accrual. Pre-
dictive and prognostic role of multiple bone formation and bone
resorption markers will be assess in this trial [31].
3.4. Basic research programs
There are currently a number of Canadian groups performing basic
and translational bone research. The overall goal of these programs is
to obtain a better understanding of changes in bone and its micro-
environment related to cancer and its treatment as well as discover
new important targets for therapeutic interventions. For example, the
Singh laboratory (McMaster University) is currently investigating
impact of glutamatergic signalling mechanisms on cancer-induced
bone pain and cancer-induced depression [32,33].
The Whyne laboratory (University of Toronto) is focused on
understanding of biomechanics of musculoskeletal system using
translational bioengineering research with emphasis on structural
changes in bone involved in metastatic process [34]. They are also
performing preclinical and Phase 1 trials assessing effects of
photodynamic therapy in metastatic bone lesions [35].
Extensive bone programs are also running at McGill University
with the Siegel laboratory identifying molecules and pathways
that facilitate organ speciﬁc breast cancer metastases [36]. This is
close collaboration with the Park laboratory where the inﬂuence
of the metastatic microenvironment on breast cancer metastasis
is being explored [37]. Finally our own group is working in
collaboration with the Kremer laboratory on a number of projects
relating to the role of vitamin D and parathyroid hormone related
peptide (PTHrP) in cancer and musculoskeletal disorders [38]. The
Addison laboratory in Ottawa are performing translational studies
look at the role of Focal Adhesion Kinase and b1 integrin in animal
bone metastases models [39].4. Discussion
Bone oncology is a broad and multidisciplinary area of cancer
therapeutics. Given the signiﬁcant impact bone health manage-
ment has across a broad range of disciplines we hope this paper
will be an important step in allowing people to see the nature of
studies available and potential collaborators. To further enhance
these communications we have also organised a yearly bone
meeting in Canada. This meeting aims to cover a wide range of
topics from normal bone function, to the effects of cancer on bone
as well as effects of cancer therapies on normal bone and
metastatic bone disease [40].
The purpose of this paper was therefore to brieﬂy review and
summarise what types of bone oncology-related trials are cur-
rently being conducted in Canada. We have speciﬁcally not
included pure bone-related basic science projects as there is no
systematic reporting structure for identifying these studies. This
is certainly something we could consider working on in the future.It is clear that the portfolio of clinical bone oncology trials is broad.
However, while most of the local therapy trials are intergroup
initiated and multicentre, the majority of systemic therapy and
bone biology trials are small, single centre studies, mainly focused
on analysis in breast cancer patients. Fortunately an increasing
number of these trials do include prospective specimen collection
for future correlative studies.
It is clear however, that if major advances are going to be made
in patient management we need more people to get involved in
these types of trials and to also ensure that sustained collabora-
tive efforts are being made. The nature of these collaborations can
be both national and international but should also occur between
diverse research groups and across multiple disciplines. For
example, our own centre has an established reputation in per-
forming bone biopsies [41,42] and thus attempts are being made
to work more closely with those groups who are experts in the
analysis of the bone structure of these specimens.
Recently a multidisciplinary consensus conference was held
around understanding bone biology and pathophysiology, pre-
vention of bone metastases and cancer treatment induced bone
loss [43]. It is clearly pleasing that the spectrum of basic and
clinical research being performed in Canada that we had shown in
this current manuscript covers almost all of consensus state-
ments. In addition, Canadian groups are making considerable
contributions to many international trials [4,23,24]. It is clear
however that if major advances are going to be made in the
treatment of patients—especially those with prostate, lung, renal
and thyroid cancers that frequently spread to bone, that we need
to change our paradigm of research. This clearly requires more
discussion and coordinated research efforts.References
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